HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $6 price target.
March 07, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevation Oncology maintains a Buy rating and a $6 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst firm like HC Wainwright & Co. can positively influence investor sentiment towards Elevation Oncology. This endorsement may lead to increased investor confidence and potential upward movement in ELEV's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100